Research Summary For patients with heavily pretreated relapsed/refractory multiple myeloma (RRMM), prior reports have shown median progression-free survival (PFS) of less than six months and median overall survival (OS) of approximately one year. Ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)–directed chimeric antigen receptor T-cell...

Research Summary Chimeric antigen receptor T-cell (CAR-T) therapy is typically administered in the inpatient setting, but accessibility to outpatient administration is expanding. Benefits of outpatient CAR-T administration include broader treatment access, cost savings, reduced healthcare burden, and potentially improved patient quality of life. Ciltacabtagene autoleucel...

Research Summary This study1 evaluated the Medicare cost impact of choosing among covalent Bruton tyrosine kinase inhibitors (cBTKis) for treatment-naïve (TN) and relapsed/refractory (RR) chronic lymphocytic leukemia (CLL). The analysis focused on differences in drug acquisition and management of grade 3 or greater adverse events...

Research Summary In this randomized, controlled, Phase III study,1 patients with resectable, epidermal growth factor receptor (EGFR)–mutated, Stage II to IIIB non-small cell lung cancer (NSCLC) were assigned 1:1:1 to receive neoadjuvant osimertinib (80mg orally once daily for at least nine weeks) plus platinum-based chemotherapy...

Research Summary Advances in T-cell redirecting therapy (TCRT), which includes chimeric antigen receptor T-cell (CAR-T) therapy and bispecific T-cell engagers (TCEs), have favorably altered the treatment landscape of multiple myeloma (MM). Previous recommendations on TCRT use in relapsed/refractory MM (RRMM) were published by the International...